<DOC>
	<DOC>NCT00991159</DOC>
	<brief_summary>The study is designed to determine the safety and tolerability of RN316 when administered intravenously to healthy adult subjects. This is the first time RN316 has been given to humans.</brief_summary>
	<brief_title>A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy, ambulatory men and women (of nonchildbearing potential) ages 18 70 inclusive. Baseline total cholesterol ≥ 200 mg/dl, baseline LDL ≥ 130 mg/dl. BMI 18.5 to 35, and body weight ≤150 kg, inclusive. Evidence of clinically significant disease that may increase the risk to the subject of study participation or interfere with interpretation of results. Secondary hyperlipidemia. Subjects who have taken lipid lowering compounds within the past 12 months prior to dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Endocrinology; Hypercholesterolemia; Hyperlipidemia; Lipid Metabolism Disorders RN316 PF-04950615</keyword>
</DOC>